Session 2: ‘Clinical impact of DNA damage repair mutations in PC’ by Professor de Bono

Related Videos

EMUC 2019

EMUC19 delivered a number of exciting sessions involving discussions on the rapidly changing treatment landscape for prostate cancer, the latest clinical trial data, new molecular biomarkers for genitourinary (GU) cancers, and the potential for non-invasive liquid biopsies (ctDNA testing) to improve diagnostic approach.

The EACCME accredited symposium, ‘ARE YOU TESTING? DNA repair alterations in prostate cancer care and cascade testing in family members’ took place at EMUC19 and was grant-funded by AstraZeneca.